Research programme: oral tryptase inhibitors - Molecumetics/Choongwae PharmaAlternative Names: Tryptase inhibitors research programme - Molecumetics/Choongwae Pharma
Latest Information Update: 19 Sep 2006
At a glance
- Originator Molecumetics
- Mechanism of Action Tryptase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Asthma; Inflammatory bowel diseases; Psoriasis
Most Recent Events
- 08 Sep 1999 This programme is available for licensing in Europe, North America and Japan (http://www.molecumetics.com)
- 08 Sep 1999 New profile
- 08 Sep 1999 Preclinical development for Asthma in USA (PO)